Immunogenicity and persistence of high-dose recombinant hepatitis B vaccine in adults infected with human immunodeficiency virus in China: A randomized, double-blind, parallel controlled trial

Vaccine ◽  
2021 ◽  
Author(s):  
Yongliang Feng ◽  
Tian Yao ◽  
Yue Chang ◽  
Linying Gao ◽  
Zhihong Shao ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis B ◽  
Controlled Trial ◽  
Hepatitis B Vaccine ◽  
High Dose ◽  
Recombinant Hepatitis ◽  
Double Blind ◽  
Immunodeficiency Virus

IMMUNOGENICITY OF HEPATITIS B VACCINE IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN

1993 ◽  
Vol 12 (10) ◽  
pp. 877 ◽  
Author(s):  
Esther P. Diamant ◽  
Clyde Schechter ◽  
David S. Hodes ◽  
Vicki B. Peters
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis B ◽  
Hepatitis B Vaccine ◽  
Immunodeficiency Virus

scholarly journals Delavirdine in Combination with Zidovudine in Treatment of Human Immunodeficiency Virus Type 1-Infected Patients: Evaluation of Efficacy and Emergence of Viral Resistance in a Randomized, Comparative Phase III Trial

2000 ◽  
Vol 44 (11) ◽  
pp. 3155-3157 ◽  
Author(s):  
Véronique Joly ◽  
Mauro Moroni ◽  
Ercole Concia ◽  
Adriano Lazzarin ◽  
Bernard Hirschel ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Controlled Trial ◽  
Antiviral Effect ◽  
Phase Iii ◽  
Cross Resistance ◽  
Double Blind ◽  
Immunodeficiency Virus

ABSTRACT We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.

Sign in / Sign up

Export Citation Format

Share Document